Cargando…

French Endocrine Society Guidance on endocrine side effects of immunotherapy

The management of cancer patients has changed due to the considerably more frequent use of immune checkpoint inhibitors (ICPIs). However, the use of ICPI has a risk of side effects, particularly endocrine toxicity. Since the indications for ICPI are constantly expanding due to their efficacy, it is...

Descripción completa

Detalles Bibliográficos
Autores principales: Castinetti, F, Albarel, F, Archambeaud, F, Bertherat, J, Bouillet, B, Buffier, P, Briet, C, Cariou, B, Caron, Ph, Chabre, O, Chanson, Ph, Cortet, C, Do Cao, C, Drui, D, Haissaguerre, M, Hescot, S, Illouz, F, Kuhn, E, Lahlou, N, Merlen, E, Raverot, V, Smati, S, Verges, B, Borson-Chazot, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347286/
https://www.ncbi.nlm.nih.gov/pubmed/30400055
http://dx.doi.org/10.1530/ERC-18-0320
_version_ 1783389916618555392
author Castinetti, F
Albarel, F
Archambeaud, F
Bertherat, J
Bouillet, B
Buffier, P
Briet, C
Cariou, B
Caron, Ph
Chabre, O
Chanson, Ph
Cortet, C
Do Cao, C
Drui, D
Haissaguerre, M
Hescot, S
Illouz, F
Kuhn, E
Lahlou, N
Merlen, E
Raverot, V
Smati, S
Verges, B
Borson-Chazot, F
author_facet Castinetti, F
Albarel, F
Archambeaud, F
Bertherat, J
Bouillet, B
Buffier, P
Briet, C
Cariou, B
Caron, Ph
Chabre, O
Chanson, Ph
Cortet, C
Do Cao, C
Drui, D
Haissaguerre, M
Hescot, S
Illouz, F
Kuhn, E
Lahlou, N
Merlen, E
Raverot, V
Smati, S
Verges, B
Borson-Chazot, F
author_sort Castinetti, F
collection PubMed
description The management of cancer patients has changed due to the considerably more frequent use of immune checkpoint inhibitors (ICPIs). However, the use of ICPI has a risk of side effects, particularly endocrine toxicity. Since the indications for ICPI are constantly expanding due to their efficacy, it is important that endocrinologists and oncologists know how to look for this type of toxicity and how to treat it when it arises. In view of this, the French Endocrine Society initiated the formulation of a consensus document on ICPI-related endocrine toxicity. In this paper, we will introduce data on the general pathophysiology of endocrine toxicity, and we will then outline expert opinion focusing primarily on methods for screening, management and monitoring for endocrine side effects in patients treated by ICPI. We will then look in turn at endocrinopathies that are induced by ICPI including dysthyroidism, hypophysitis, primary adrenal insufficiency and fulminant diabetes. In each chapter, expert opinion will be given on the diagnosis, management and monitoring for each complication. These expert opinions will also discuss the methodology for categorizing these side effects in oncology using ‘common terminology criteria for adverse events’ (CTCAE) and the difficulties in applying this to endocrine side effects in the case of these anti-cancer therapies. This is shown in particular by certain recommendations that are used for other side effects (high-dose corticosteroids, contraindicated in ICPI for example) and that cannot be considered as appropriate in the management of endocrine toxicity, as it usually does not require ICPI withdrawal or high-dose glucocorticoid intake.
format Online
Article
Text
id pubmed-6347286
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-63472862019-01-28 French Endocrine Society Guidance on endocrine side effects of immunotherapy Castinetti, F Albarel, F Archambeaud, F Bertherat, J Bouillet, B Buffier, P Briet, C Cariou, B Caron, Ph Chabre, O Chanson, Ph Cortet, C Do Cao, C Drui, D Haissaguerre, M Hescot, S Illouz, F Kuhn, E Lahlou, N Merlen, E Raverot, V Smati, S Verges, B Borson-Chazot, F Endocr Relat Cancer Guidelines and Guidance The management of cancer patients has changed due to the considerably more frequent use of immune checkpoint inhibitors (ICPIs). However, the use of ICPI has a risk of side effects, particularly endocrine toxicity. Since the indications for ICPI are constantly expanding due to their efficacy, it is important that endocrinologists and oncologists know how to look for this type of toxicity and how to treat it when it arises. In view of this, the French Endocrine Society initiated the formulation of a consensus document on ICPI-related endocrine toxicity. In this paper, we will introduce data on the general pathophysiology of endocrine toxicity, and we will then outline expert opinion focusing primarily on methods for screening, management and monitoring for endocrine side effects in patients treated by ICPI. We will then look in turn at endocrinopathies that are induced by ICPI including dysthyroidism, hypophysitis, primary adrenal insufficiency and fulminant diabetes. In each chapter, expert opinion will be given on the diagnosis, management and monitoring for each complication. These expert opinions will also discuss the methodology for categorizing these side effects in oncology using ‘common terminology criteria for adverse events’ (CTCAE) and the difficulties in applying this to endocrine side effects in the case of these anti-cancer therapies. This is shown in particular by certain recommendations that are used for other side effects (high-dose corticosteroids, contraindicated in ICPI for example) and that cannot be considered as appropriate in the management of endocrine toxicity, as it usually does not require ICPI withdrawal or high-dose glucocorticoid intake. Bioscientifica Ltd 2018-10-08 /pmc/articles/PMC6347286/ /pubmed/30400055 http://dx.doi.org/10.1530/ERC-18-0320 Text en © 2018 The authors http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/) .
spellingShingle Guidelines and Guidance
Castinetti, F
Albarel, F
Archambeaud, F
Bertherat, J
Bouillet, B
Buffier, P
Briet, C
Cariou, B
Caron, Ph
Chabre, O
Chanson, Ph
Cortet, C
Do Cao, C
Drui, D
Haissaguerre, M
Hescot, S
Illouz, F
Kuhn, E
Lahlou, N
Merlen, E
Raverot, V
Smati, S
Verges, B
Borson-Chazot, F
French Endocrine Society Guidance on endocrine side effects of immunotherapy
title French Endocrine Society Guidance on endocrine side effects of immunotherapy
title_full French Endocrine Society Guidance on endocrine side effects of immunotherapy
title_fullStr French Endocrine Society Guidance on endocrine side effects of immunotherapy
title_full_unstemmed French Endocrine Society Guidance on endocrine side effects of immunotherapy
title_short French Endocrine Society Guidance on endocrine side effects of immunotherapy
title_sort french endocrine society guidance on endocrine side effects of immunotherapy
topic Guidelines and Guidance
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347286/
https://www.ncbi.nlm.nih.gov/pubmed/30400055
http://dx.doi.org/10.1530/ERC-18-0320
work_keys_str_mv AT castinettif frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT albarelf frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT archambeaudf frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT bertheratj frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT bouilletb frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT buffierp frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT brietc frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT carioub frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT caronph frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT chabreo frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT chansonph frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT cortetc frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT docaoc frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT druid frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT haissaguerrem frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT hescots frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT illouzf frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT kuhne frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT lahloun frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT merlene frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT raverotv frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT smatis frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT vergesb frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy
AT borsonchazotf frenchendocrinesocietyguidanceonendocrinesideeffectsofimmunotherapy